Stock Events

Stock Events

4D Molecular Therapeutics 

$9.81
17
+$0.5+5.37% Today

Statistics

Day High
9.86
Day Low
9.47
52W High
12.34
52W Low
2.24
Volume
135,336
Avg. Volume
787,722
Mkt Cap
560.49M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

7MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-1.01
-0.53
-0.05
0.43
Expected EPS
-1.00375
Actual EPS
N/A

Financials

-434,778.38%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
74,000Revenue
-321.74MNet Income

Analyst Ratings

$30.20Average Price Target
The highest estimate is 36.00.
From 5 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow FDMT. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Sangamo Therapeutics
SGMO
Mkt Cap180.42M
Sangamo Therapeutics, Inc. focuses on genomic medicine, including gene therapy, competing in similar therapeutic areas as FDMT.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.29B
BioMarin Pharmaceutical Inc. develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions, including gene therapies.
Pfizer
PFE
Mkt Cap140.15B
Pfizer Inc., through its acquisition of Bamboo Therapeutics and Spark Therapeutics, has expanded into gene therapy, competing in the same space as FDMT.
Solid Biosciences
SLDB
Mkt Cap419.71M
Solid Biosciences Inc. is focused on treatments for Duchenne muscular dystrophy, including gene therapies, competing with FDMT's approach.
Intellia Therapeutics
NTLA
Mkt Cap1.35B
Intellia Therapeutics, Inc. is a leading genome editing company, which competes indirectly by offering alternative treatments to genetic disorders targeted by FDMT.
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
CRISPR Therapeutics AG focuses on the development of gene-based therapies using CRISPR/Cas9 technology, offering competitive alternatives to FDMT's gene therapy products.

About

4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.
Show more...
CEO
Dr. John F. Milligan Ph.D.
Employees
227
Country
US
ISIN
US35104E1001

Listings

XNAS
US
FDMT
BOATS
BOATS
FDMT.BOATS

0 Comments

Share your thoughts

FAQ

What is 4D Molecular Therapeutics stock price today?▼
The current price of FDMT is $9.81 USD — it has increased by +5.37% in the past 24 hours. Watch 4D Molecular Therapeutics stock price performance more closely on the chart.
What is 4D Molecular Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange 4D Molecular Therapeutics stocks are traded under the ticker FDMT.
Is 4D Molecular Therapeutics stock price growing?▼
FDMT stock has fallen by -1.11% compared to the previous week, the month change is a +1.14% rise, over the last year 4D Molecular Therapeutics has showed a +226.76% increase.
What is 4D Molecular Therapeutics market cap?▼
Today 4D Molecular Therapeutics has the market capitalization of 560.49M
When is the next 4D Molecular Therapeutics earnings date?▼
4D Molecular Therapeutics is going to release the next earnings report on May 07, 2026.
What were 4D Molecular Therapeutics earnings last quarter?▼
FDMT earnings for the last quarter are 0.43 USD per share, whereas the estimation was -0.53 USD resulting in a +181.44% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is 4D Molecular Therapeutics revenue for the last year?▼
4D Molecular Therapeutics revenue for the last year amounts to 74,000 USD.
What is 4D Molecular Therapeutics net income for the last year?▼
FDMT net income for the last year is -321.74M USD.
How many employees does 4D Molecular Therapeutics have?▼
As of April 01, 2026, the company has 227 employees.
In which sector is 4D Molecular Therapeutics located?▼
4D Molecular Therapeutics operates in the Health Care sector.
When did 4D Molecular Therapeutics complete a stock split?▼
4D Molecular Therapeutics has not had any recent stock splits.
Where is 4D Molecular Therapeutics headquartered?▼
4D Molecular Therapeutics is headquartered in EmeryVille, US.